Juergen Soutschek PhD

Dr. Soutschek did his PhD thesis in developmental neurobiology at the MaxPlanck-Institute for Developmental Biology in Tubingen, Germany. Since then he held various leading R&D positions at several gene silencing pioneers such as Devgen, Ribopharma, Alnylam or Regulus Therapeutics, and contributed significantly to the advancement of RNA technologies as therapeutics. At ugichem where a new and promising PNA based chemistry has been developed Dr. Soutschek is responsible for preclinical research and development.